Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accumulated Expenses (2016 - 2025)

Cytosorbents (CTSO) has disclosed Accumulated Expenses for 14 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 37.18% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Sep 2025, down 37.18%, and an annual FY2024 reading of $6.0 million, down 23.36% over the prior year.
  • Accumulated Expenses was $3.5 million for Q3 2025 at Cytosorbents, down from $6.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.4 million in Q1 2022 and bottomed at $3.5 million in Q3 2025.
  • Average Accumulated Expenses over 5 years is $7.3 million, with a median of $7.5 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 49.85% in 2021, then tumbled 37.18% in 2025.
  • Year by year, Accumulated Expenses stood at $7.4 million in 2021, then increased by 6.76% to $8.0 million in 2022, then decreased by 1.01% to $7.9 million in 2023, then decreased by 23.36% to $6.0 million in 2024, then plummeted by 42.57% to $3.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for CTSO at $3.5 million in Q3 2025, $6.0 million in Q4 2024, and $5.5 million in Q3 2024.